Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has decided to venture into the real estate sector with the ...

Courtesy Staci Rice, Classified as a GLP-1, appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes drug Ozempic.

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy, in May 2022 and lost a staggering 64lbs in six months. But then she made a big ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy. The notice was issued on Tuesday ...

Ozempic (semaglutide) has gained significant attention as an effective weight loss aid, but many individuals are now asking a crucial question: What happens to weight loss once the medication is ...

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Rybelsus is an oral tablet best taken on an empty stomach. Avoiding certain types of food in your diet may help manage blood sugar levels and minimize certain side effects of the drug. Limiting ...

But the semaglutide-like drugs also appear to increase the risk of many others. Glucagon-like peptide 1 receptor agonists (called simply GLP-1RAs), the class to which those drugs and others including ...

ISLAMABAD -- Relations between Pakistan and Bangladesh are experiencing a historic thaw following the ouster of Bangladeshi Prime Minister Sheikh Hasina last August. Exchanges of officials are ...

Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

The European Medicines Agency (EMA) says its safety committee has begun a review into reports of an association between use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and a ...